Dual-faced CXCL5 holds the key to unlocking immunotherapy in obese pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, characterized by a profoundly immunosuppressive tumor microenvironment and resistance to immunotherapy. Obesity, a modifiable risk factor that increases PDAC incidence,…